IMW 2019
Conference Correspondent | September 24, 2019
Researchers report promising findings for a novel quad regimen, D-RVd, compared with RVd in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem-cell transplant.
Conference Correspondent | September 24, 2019
A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM).
Conference Correspondent | September 24, 2019
New data suggest that combinations using a subcutaneous (SC) co-formulation of daratumumab with recombinant human hyaluronidase have similar clinical activity and safety as intravenous daratumumab in patients with newly diagnosed multiple myeloma (MM).
Conference Correspondent | September 24, 2019
This first-in-human study shows that AMG 420, a BiTE antibody that directs the immune system to target B-cell maturation antigen (BCMA) on the tumor cell and CD3 on T-cells, may be effective and safe.
Conference Correspondent | September 24, 2019
Researchers report positive data for patients with relapsed or refractory multiple myeloma (RRMM) and extramedullary disease in the phase 2 HORIZON study of melflufen plus dexamethasone.
Conference Correspondent | September 24, 2019
This phase 1 study demonstrates that CT053, a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell product, is effective and safe in patients with multiply relapsed multiple myeloma (MM).
Conference Correspondent | September 24, 2019
This study reports successful administration of intravenous daratumumab over 90 minutes for patients with relapsed or refractory multiple myeloma (RRMM).
Results 1 - 7 of 7
